Fecal transplant with immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a fecal microbiota transplant (FMT) — transferring healthy bacteria from a donor's stool into your gut — combined with the immunotherapy drug tislelizumab can help treat advanced non-small cell lung cancer (NSCLC) that has progressed after prior treatments. It aims to see if this combination can improve outcomes by boosting your immune system's response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has gotten worse after at least one round of chemotherapy and after immunotherapy treatment.
- If you have EGFR or ALK mutations, you must have already tried the approved targeted therapies for these mutations and your cancer still progressed.
- You have at least one measurable tumor (as defined by standard criteria).
- You are in generally good health (ECOG performance status 0 or 1) and have a life expectancy of at least 3 months.
- Your blood and organ function meet certain minimum levels (e.g., adequate white blood cell count, hemoglobin, platelets, kidney and liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving patients a fecal microbiota transplant (healthy bacteria from stool of patients who responded to immunotherapy) before standard immunotherapy is safe and feasible for stage II-III lung cancer. It may improve how well the immune system fights cancer.
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.